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Introduction {#sec1}
============

Eukaryotic and prokaryotic cells alike possess the ability to alter their phenotypes through global changes in gene expression. In bacteria, these transitions enable survival during stress conditions, drive developmental programs, and promote infection of host organisms. One common mechanism bacteria utilize to effect large-scale changes in gene expression is through alternative sigma (σ) factor subunits of RNA polymerase (RNAP). The dissociable RNAP sigma factor subunit is responsible for recognition of promoter DNA and the subsequent initiation of transcription. Most sigma factors are members of the σ^70^ superfamily, which is subdivided into four classes based upon conservation and the presence/absence of the conserved sigma domains (σ1.1, σ2, σ3, and σ4) that mediate interactions with RNAP and/or promoter DNA (reviewed in [@bib13], [@bib33]). All bacteria employ an essential primary sigma factor (class I) that directs transcription of housekeeping genes; many bacteria also possess alternative sigma factors (classes II, III, and IV) that compete for binding to RNAP and redirect it to transcribe sets of genes required for adaptive responses. Hence, the suite of genes expressed in a bacterial cell can be reprogrammed by manipulating the levels, activity, or availability of alternative sigma factors (reviewed in [@bib31]).

One prevalent form of post-translational regulation of alternative sigma factors occurs via anti-sigma factors: proteins that bind to and prevent their cognate sigma factor from interacting with RNAP. Unlike sigma factors, which share sequence, structural, and functional conservation, anti-sigma factors are more diverse in their sequences, structures, and/or mode of sigma factor inhibition (reviewed in [@bib33]). A number of structural and bioinformatics analyses have revealed that anti-sigma factors for the class IV extracytoplasmic function (ECF) sigma factors often share one of two conserved anti-sigma domain structures, despite little sequence conservation (reviewed in [@bib5]). Less is known, however, of the structural features of anti-sigma factors that antagonize non-class IV alternative sigma factors, given the limited number of structures determined to date ([@bib8], [@bib30], [@bib43]).

Here, we have structurally analyzed CsfB (also called Gin), a small, Zn^2+^-binding anti-sigma factor that inhibits two class III alternative sigma factors during spore formation by the model bacterium *Bacillus subtilis* ([Figure 1](#fig1){ref-type="fig"}A) ([@bib9], [@bib10], [@bib22], [@bib36], [@bib40], [@bib39]). In the forespore cell (the nascent spore), CsfB binds and inhibits the late-acting sigma factor σ^G^, helping to ensure that it does not become active before the early-acting sigma factor σ^F^ has completed its program of gene expression ([@bib22], [@bib36]). In the mother cell, which helps support the development of the forespore, CsfB binds the early-acting sigma factor σ^E^, helping to inactivate it after the switch to σ^K^ ([@bib39]). Here, we report the structure of CsfB and characterize its interaction with σ^G^ and σ^E^.Figure 1The Anti-sigma Factor CsfB Helps to Orchestrate the Switch from Early to Late Gene Expression during *B. subtilis* Sporulation(A) Cartoon depiction of the role of the dual-specificity anti-sigma factor CsfB in regulating the transition from early to late gene expression during *B. subtilis* sporulation. Early in sporulation (reviewed in [@bib45]), an asymmetric cell division event produces two cells: a smaller forespore (the nascent spore) and a larger mother cell. Initially, these two cells lie side-by-side; the mother cell then engulfs the forespore in a phagocytic-like process. At early times, σ^F^ and σ^E^ drive gene expression in the forespore and mother cell, respectively. Among the genes activated by σ^F^ and σ^E^ are those encoding the late-acting sigma factors, σ^G^ and σ^K^, respectively (dashed arrows). The anti-sigma factor CsfB is expressed in both compartments under the control of σ^F^ and σ^K^ (dashed arrows). In the forespore, CsfB antagonizes σ^G^ at early times (barred line). In the mother cell, CsfB antagonizes σ^E^ at later times (barred line).(B) ^1^H-^15^N HSQC spectrum of CsfB (orange). Full assignment of the cleaved CsfB version appears in black (CsfB^1−48^), partial assignment of the residual full-length CsfB in blue and the tag residues in gray; sc denotes side chain resonances. The C-terminal residue from the cleaved version (A48) is highlighted by a green square.

Results {#sec2}
=======

Recombinant CsfB Degrades to a Stable but Nonfunctional Domain {#sec2.1}
--------------------------------------------------------------

We produced recombinant N-terminally histidine-tagged full-length CsfB (residues 1--64), but the protein consistently degraded to a stable product comprising residues 1--48. The gradual disappearance of the C-terminal 16-amino acid fragment was confirmed by electrospray ionization mass spectrometry ([Figure S1](#mmc1){ref-type="supplementary-material"}) and nuclear magnetic resonance (NMR) backbone assignment indicated that the predominant C-terminal residue was A48 ([Figure 1](#fig1){ref-type="fig"}B). We predicted that this shorter form of CsfB (CsfB^1−48^) was nonfunctional, given the absence of residues required for σ^G^ inhibition ([@bib36]). To confirm this, we assessed the ability of CsfB^1−48^ to inhibit σ^G^ or σ^E^ when the proteins were co-expressed during vegetative growth of *B. subtilis*, an approach that has been used previously ([@bib22], [@bib36]). Whereas wild-type CsfB inhibited \>99% of σ^G^ activity and ∼77% of σ^E^ activity, the CsfB^1−48^ variant displayed no inhibition of either sigma factor ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Isolation of a Functional, Full-Length CsfB Protein *In Vitro* {#sec2.2}
--------------------------------------------------------------

Since CsfB^1−48^ was unable to inhibit σ^G^ and σ^E^, we adopted several approaches to obtain a full-length, stable version of CsfB. Initially, we produced a C-terminally histidine-tagged version of CsfB, which was slower to degrade but still consistently converted to the CsfB^1−48^ species ([Figure S3](#mmc1){ref-type="supplementary-material"}). We next rationally designed a panel of CsfB variants ([Table S1](#mmc1){ref-type="supplementary-material"}) to identify a functional version of CsfB that remained full-length. Of these, A48E (altered at the known cleavage point) proved the most successful, yielding a stable full-length version of CsfB that remained intact for 4 days as confirmed by mass spectrometry ([Figure S1](#mmc1){ref-type="supplementary-material"}). CsfB^A48E^ inhibited both σ^G^ and σ^E^ to the same extent as wild-type CsfB *in vivo* ([Figure S2](#mmc1){ref-type="supplementary-material"}), suggesting that the A48E substitution does not alter protein function. Satisfyingly, the NMR HSQC spectrum of CsfB^A48E^ overlaid precisely with that of CsfB^1−48^ (truncated wild-type), except for the presence of peaks corresponding to the additional C-terminal residues ([Figure S4](#mmc1){ref-type="supplementary-material"}). Some of these additional peaks could be assigned from triple-resonance experiments and, upon revisiting earlier HSQC spectra of freshly purified wild-type CsfB, a low population of these same peaks was visible from the residual full-length protein that had not yet degraded ([Figure 1](#fig1){ref-type="fig"}B). Several peaks within the C-terminal region could not be assigned due to a line-broadening effect ([Figure S4](#mmc1){ref-type="supplementary-material"}B). The new C-terminal peaks, whether assignable or not, displayed little dispersion in the proton dimension, a hallmark of low structural complexity.

Interaction of CsfB^A48E^ with σ^G^ and σ^E^ {#sec2.3}
--------------------------------------------

With the functional, full-length CsfB^A48E^ protein in hand, we first analyzed its interactions with its target sigma factors. To this end, we produced recombinant full-length σ^G^ (residues 1--260) and a truncated version of σ^E^ (residues 17--239) lacking the N-terminal membrane-anchored pro-sequence ([@bib35]). We then carried out NMR chemical shift perturbation (CSP) analysis between unlabeled σ^G^ or σ^E^ and ^15^N-labeled CsfB^A48E^. Titration of unlabeled σ^G^ caused the majority of CsfB^A48E^ backbone amide signals to gradually disappear ([Figure 2](#fig2){ref-type="fig"}A). This result indicates an interaction between CsfB^A48E^ and σ^G^, although the disappearance of most peaks prevented identification of specific positions on CsfB^A48E^ that mediate contact. As a control, we performed CSP analysis between unlabeled σ^G^ and ^15^N-labeled CsfB^1−48^, the truncated variant incapable of inhibiting σ^G^ *in vivo*. Consistent with the inability of these proteins to interact, no changes to the CsfB^1−48^ backbone amide signals were observed.Figure 2Interactions of CsfB^A48E^ with σ^G^ and σ^E^(A and B) Overlay of ^1^H-^15^N SOFAST HMQC spectra of ^15^N-labeled CsfB^A48E^ alone (blue), and in presence of 2-fold molar excess of (A) σ^G^ (red) or (B) σ^E^ (purple). Extra peaks appearing upon titration with σ^E^ are highlighted by a green square.(C and D) ITC thermograms of interaction between CsfB^A48E^ and (C) σ^G^ or (D) σ^E^. Raw data (upper panels), binding isotherm (lower panels). Fitted data for CsfB^A48E^-σ^E^ interaction: ΔH = −8.04 ± 0.04 kcal/mol; ΔS = 9.19 ± 0.50 cal/(mol·K); N = 1.01 ± 0.00 sites.

When ^15^N-labeled CsfB^A48E^ was titrated with unlabeled σ^E^, many CsfB^A48E^ backbone amide signals decreased in intensity and shifted position significantly ([Figure 2](#fig2){ref-type="fig"}B), indicating a tight interaction in the nanomolar to low micromolar affinity range. As a result of the slow timescale, it was not possible to reliably assign the peaks in their new positions and, unfortunately, the resulting complex was too large for the triple-resonance experiments required to assign the bound state. Hence, we could not assess the relative contributions of each of the bound residues. However, we noted that addition of σ^E^ caused several of the peaks corresponding to CsfB^A48E^ residues 49--64 to shift to the ^1^H upfield region of the spectrum ([Figure 2](#fig2){ref-type="fig"}B), suggesting that the C-terminal region becomes more structured upon interaction with σ^E^. As expected, σ^E^ caused no shifts in the spectrum of the ^15^N-labeled CsfB^1−48^ truncated variant.

We next carried out isothermal titration calorimetry (ITC) to quantify the interaction between CsfB^A48E^ and its two cognate sigma factors. The CsfB^A48E^-σ^E^ interaction was determined to have a K~d~ of 12.5 ± 2.4  nM ([Figure 2](#fig2){ref-type="fig"}D) and 1:1 stoichiometry. CsfB^A48E^ and σ^G^ also showed clear evidence of an interaction ([Figure 2](#fig2){ref-type="fig"}C), although a K~d~ and stoichiometry could not be determined, possibly due to instability or aggregation of our recombinant σ^G^. However, by comparing the ITC data to σ^E^ experiments, we can conclude that the CsfB^A48E^-σ^G^ binding affinity is likely within the same order of magnitude. As a control, we verified that no interaction was observed between the truncated variant CsfB^1−48^ and σ^G^ or σ^E^ under the same conditions.

NMR Solution Structure of CsfB {#sec2.4}
------------------------------

Next, we sought to solve the solution structure of CsfB. Despite having isolated a functional, full-length CsfB variant (CsfB^A48E^), we could only obtain high-quality NMR triple-resonance signals for residues comprising the originally purified, truncated CsfB^1−48^ variant. Given that the C-terminal 16 residues presented low structural complexity, and the folding of the rest of the protein was conserved, we opted to complete the full NMR assignments (BMRB: [34102](ncbi-mmdb:34102){#intref0010}) and solve the solution structure for CsfB residues 1--48. It forms a tight symmetrical homodimer ([Figures 3](#fig3){ref-type="fig"}A and 3B; PDB: [5N7Y](pdb:5N7Y){#intref0015}; structural statistics in [Table 1](#tbl1){ref-type="table"}), where each monomer consists of a treble-clef zinc finger motif ([@bib17]).Figure 3NMR Solution Structure of the CsfB^1−48^ Dimer and Functionality of Dimerization-Deficient CsfB Variants(A) Orthogonal views of ensemble backbone (left) and cartoon (right) representations for the 20 lowest energy ARIA-calculated structures as deposited in the PDB (PDB: [5N7Y](pdb:5N7Y){#intref0135}).(B) Detailed view of the dimer interface; hydrophobic buried residues are depicted using ball and stick representation.(C) Detailed view of the zinc finger coordination shell showing the cysteine residues and the Sγ(i)-HN(i+2) hydrogen bonds (green dashed lines) in the first and second spheres of coordination.(D and E) CsfB variants lacking putative dimerization residues V37 and/or I38 are deficient for sigma factor inhibition *in vivo*. Vegetatively growing *B. subtilis* cells were induced with IPTG to express (D) σ^G^ or (E) σ^E^ alone or in combination with wild-type or variant CsfB. Sigma factor activity was monitored by light production (measured in relative light units \[RLU\]) from σ^G^- or σ^E^-dependent luciferase reporter genes (P~*sspB*~*-lux* or P~*spoIID*~*-lux*, respectively). Control strains lacking inducible constructs ("Reporter alone") are shown for comparison in each graph. Error bars indicate SD. Strains used in this assay are listed in [Table S5](#mmc1){ref-type="supplementary-material"}.Table 1NMR and Refinement Statistics for the Final 20 Ensemble Structures of CsfB**NMR Distance and Dihedral Constraints (per Monomer)**Distance constraintsTotal unambiguous constraints1,154 Intra-residue417 Sequential (\|i-j\| = 1)231 Medium-range (1 \< \|i-j\| \< 4)118 Long-range (\|i-j\| \> 5)201 Intermolecular187Ambiguous constraints116TALOS-derived dihedral constraintsTotal dihedral constraints (Φ+Ψ)64**Structure Statistics**Violations per structure (mean and SD)Number of violated distance restraints (\>0.25 Å)0.65 ± 0.63 Max. distance constraint violation0.28 ÅNumber of violated dihedral angle restraints (\>5°)2.3 ± 0.9 Max. dihedral angle violation9.2°Ramachandran plot analysis[a](#tblfn1){ref-type="table-fn"}Residues 8--40Residues in most favored regions89.5% ± 4.0%Residues in additionally allowed regions10.5% ± 4.0%Residues in disallowed regions0.0% ± 0.0%Derivation from idealized geometryBond length (Å)0.0079 ± 0.0005Bond angles (°)0.83 ± 0.05Average RMSD to mean structure (range 8--40)Backbone0.5 ± 0.2Heavy1.1 ± 0.2[^3]

The folded domain (residues 8--40) of each CsfB monomer contains two β hairpins separated by a short turn, followed by a C-terminal α helix. The structure clearly indicates that each monomer binds a Zn^2+^ ion; we confirmed a 1:1 Zn^2+^:CsfB ratio by ICP-MS. Zinc binding by CsfB involves the coordination of two cysteine residues from the first β-hairpin knuckle (C11 and C14) and two additional cysteines from the first turn of the α helix (C30 and C33) in a tetrahedral conformation ([Figure 3](#fig3){ref-type="fig"}C), a classic treble-clef zinc finger fold ([@bib27], [@bib23]). The chemical shift values for ^13^Cα (∼59 ppm) and ^13^Cβ (∼31 ppm) are consistent with zinc-binding character ([@bib26]). The second coordination shell is defined by the formation of two hydrogen bonds between the cysteine sulfur atoms (C11 and C30) and the amide group of the residue at position +2 (I13 and D32, respectively). For all zinc coordination parameters, see [Table S2](#mmc1){ref-type="supplementary-material"}.

The CsfB homodimer interface spans 1,138 Å^2^ (calculated by PISA; [@bib28]) and involves numerous intermolecular contacts between the β hairpins and α helices of each monomer ([Figure 3](#fig3){ref-type="fig"}B). Several nonpolar residues (V12, I13, I22, L24, I26, V37, I38) are embedded in the dimer interface, creating a hydrophobic core resembling that of a globular protein. In contrast, the surface of the protein displays hydrophilic side chains that create an intricate network of polar contacts. For example, the ɛ-amino group of K36 from one monomer is surrounded by the carboxylate side chain of D32 from the same chain and the hydroxyl group of Y25 from the other monomer. In addition, the side chains of K27 from one monomer and D15 from the other chain, as well as those from S41 and E34, form clear polar contacts.

Finally, we tested the effect of disrupting CsfB dimer formation in *B. subtilis* by constructing CsfB variants with substitutions at V37 and/or I38. These two residues in the α helix of one CsfB monomer pack against the same two residues in the α helix of the second monomer; these two positions are almost always occupied by hydrophobic residues in CsfB homologs ([@bib36], [@bib4]). We found that the individual alanine substitutions (V37A and I38A) had only modest effects on CsfB-mediated inhibition of σ^G^ or σ^E^ in the vegetative co-induction assay ([Figures 3](#fig3){ref-type="fig"}D and 3E). In contrast, substitution of these residues with glutamate (V37E and I38E) significantly reduced inhibition of σ^G^ from nearly 100% to 0% and 15%, respectively. CsfB-mediated inhibition of σ^E^ was also significantly compromised by the V37E substitution (reduced from 77% to 9%), while the I38E had a more modest effect on inhibition (reducing it from 77% to 49%; [Figures 3](#fig3){ref-type="fig"}D and 3E). Lastly, we found that simultaneous substitution of these positions for alanine (V37A, I38A), also significantly diminished CsfB-dependent σ^G^ and σ^E^ inhibition, to only 17% and 32%, respectively. These findings imply that dimer formation by CsfB is required for inhibition of σ^G^ and σ^E^.

Discussion {#sec3}
==========

Here, we have solved the solution structure of the folded domain of the anti-sigma factor CsfB, which inhibits two class III sigma factors, σ^G^ and σ^E^, during *B. subtilis* sporulation. The two conserved C-X-X-C motifs of CsfB suggested early on that it was likely to bind Zn^2+^ ([@bib22]), a prediction that was verified biochemically in two studies, albeit with different Zn^2+^:CsfB ratios reported ([@bib36], [@bib40]). Genetic analyses further hinted that CsfB might function as a dimer ([@bib36]). Our solved structure verifies that CsfB is a symmetric homodimer, with each monomer adopting a treble-clef zinc finger fold coordinating a single Zn^2+^ ion. We confirmed a 1:1 Zn^2+^:CsfB ratio by ICP-MS, in line not only with our structure but also with the 1:1 Zn^2+^:CsfB ratio reported by [@bib40]. Our CsfB structure also offers an explanation for the finding by [@bib36] that mutating the highly conserved glycine at position 21 to cysteine abolished CsfB function. The two alpha protons in this glycine point snugly into the hydrophobic core of the protein such that any other side chain at this position would likely cause a steric hindrance.

Our CsfB structure is inconsistent, however, with a model proposed by [@bib36] in which CsfB forms an asymmetric dimer that coordinates a single Zn^2+^ ion between different cysteine pairs on alternative monomers. This model was a sensible interpretation of data from a series of cysteine deletion mutants co-expressed *in vivo*, as well as their measurement of a 0.5:1 Zn^2+^:CsfB ratio. Given that our NMR data clearly show the presence of a symmetric dimer (one subset of signals), we suspect that the Zn^2+^:CsfB ratio reported by these authors may be an artifact of their maltose-binding protein-CsfB fusion, the functionality of which was not reported. Alternatively, it may be that purification of CsfB from sporulating *B. subtilis* accounts for the altered zinc content in the [@bib36] study; our CsfB protein and that of [@bib40] were purified from *Escherichia coli*. In this case, it would be tempting to speculate that CsfB is subject to Zn^2+^-dependent regulation during sporulation of *B. subtilis*, as has been suggested previously ([@bib22]).

The CsfB and ClpX N-Terminal Domain Treble-Clef Dimers Are Structurally Similar {#sec3.1}
-------------------------------------------------------------------------------

We have found here that CsfB adopts a treble-clef zinc finger fold, one of the most common zinc finger arrangements ([@bib23], [@bib27]). Interestingly, CsfB appears most similar to the N-terminal domain (NTD) of the *E. coli* AAA + ATPase ClpX (PDB: [2DS5](pdb:2DS5){#intref0020}--[2DS8](pdb:2DS8){#intref0025}) ([@bib34]); to our knowledge, CsfB and the ClpX NTD are the only examples of dimerization found in the treble-clef zinc finger fold family (as identified by the Dali server \[[@bib20], [@bib21]\]). ClpX is the chaperone/unfoldase component of the ClpXP protease, a barrel-shaped proteolytic machine that degrades target proteins for quality control as well as regulation ([@bib2]). It is proposed that the dimerized ClpX NTDs interact with substrates or cofactors of ClpXP and guide them toward the protease complex for degradation ([@bib46]).

CsfB and the ClpX NTD (PDB: [2DS6](pdb:2DS6){#intref0030}) structurally align with a root-mean-square deviation (RMSD) of 4.4 Å (backbone alignment between CsfB 8--43 and CplX 11--49 residues over 196 atoms) and share a sequence identity of ∼20% ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}). Both homodimerize via a hydrophobic core of residues derived from their C-terminal α helices and two β hairpins. The proteins have a similar area of dimer interface at 945 Å^2^ for the ClpX NTD ([@bib12]) and 1,138 Å^2^ for CsfB. Although both dimers are held together with a combination of hydrophobic and electrostatic interactions, the pattern of these interactions is disparate ([Figures 4](#fig4){ref-type="fig"}B and 4C) casting doubt on their evolutionary relatedness. This, together with poor conservation of solvent-exposed residues, may indicate that the similarity between the CsfB and ClpX NTD dimers is limited to their structural folds, and does not extend to binding partners and/or function.Figure 4Structural and Sequence Comparison of CsfB with ClpX_NTD(A) Sequence alignment of CsfB and ClpX_NTD from different species. Cartoons above the sequences represent the positions involved in secondary structure formation in CsfB.(B and C) Structural comparison of dimer interfaces in CsfB (orange and blue, top) and ClpX_NTD (PDB: [2DS6](pdb:2DS6){#intref0140}, light yellow and cyan, bottom). Zinc cations shown as gray spheres. Residues involved in (B) antiparallel helices packaging and (C) loop contacts are shown for each.

CsfB as an Anti-sigma Factor Structure {#sec3.2}
--------------------------------------

To our knowledge, CsfB is only the third anti-sigma factor for class III alternative sigma factors to be structurally analyzed, with the other two being the *Bacillus stereothermophilus* σ^F^ sporulation anti-sigma factor SpoIIAB ([@bib8], [@bib30]) and the *Aquifex aeolicus* σ^28^ flagellum biosynthesis anti-sigma factor FlgM ([@bib43]). CsfB is unrelated to both of these proteins, although SpoIIAB also homodimerizes ([@bib6], [@bib8]). Aside from the ability to coordinate Zn^2+^, CsfB also displays no structural similarity to the zinc anti-sigma (ZAS) family of anti-sigma factors that inhibit class IV ECF alternative sigma factors ([@bib7], [@bib42]). Lastly, we had previously noted that CsfB resembles the *B. subtilis* σ^F^ inhibitor Fin at the primary amino acid sequence level ([@bib4]). However, comparison of the CsfB structure with our recently reported Fin structure reveals that, although both proteins bind zinc, they fold into completely different motifs ([@bib49]).

Sigma Factor Inhibition by CsfB {#sec3.3}
-------------------------------

Our ultimate objective is a complete understanding of the mechanism by which CsfB inhibits σ^G^ and σ^E^ during *B. subtilis* sporulation, and the regulation thereof. This study made significant headway toward this goal. We have shown that CsfB forms a tight homodimer that binds tightly to its two target sigma factors. In the case of the CsfB-σ^E^ interaction, our ITC analysis indicated a stoichiometry of 1:1, suggesting that a CsfB dimer simultaneously binds two σ^E^ molecules. We find the alternative scenario, in which the CsfB dimer dissociates upon binding σ^E^, to be unlikely given that the CsfB HSQC spectrum does not drastically reconfigure upon addition of σ^E^. Whether σ^G^ is bound in a similar manner remains an open question, given that we could neither calculate a stoichiometry from our ITC data nor observe the CsfB bound state by NMR.

Our data do not yet allow us to draw precise conclusions regarding the interface of CsfB that mediates contact with σ^E^ or σ^G^. That said, it is evident that the C-terminal region of CsfB is required for interaction with both sigma factors *in vitro* and their inhibition *in vivo*. Our CSP analysis further indicates that this C-terminal region of CsfB becomes more structured upon interaction with σ^E^. We therefore speculate that, at least for σ^E^, two sigma factors are bound, one apiece, to the two C-terminal "tails" of a CsfB dimer. Interestingly, evidence in the literature suggests that the interaction of CsfB with σ^G^ is likely to be dissimilar, at least in its detail. CsfB binds to σ^G^ at region 2.1 while it binds to σ^E^ at regions 2.2--2.3. Moreover, specific amino acids that help CsfB discriminate between σ^F^ and σ^G^ play no role in discriminating between σ^E^ and σ^K^, and vice versa ([@bib40], [@bib39]). As such, comparing and contrasting the structural basis for σ^G^ and σ^E^ inhibition by CsfB is an exciting challenge for future work.

Last but not least, it is tempting to speculate that degradation/cleavage of CsfB, which posed a significant challenge in this study, may be physiologically relevant in *B. subtilis*. For example, cleavage/degradation of CsfB may provide a mechanism by which σ^G^ ultimately escapes CsfB inhibition at late times in the forespore.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains***E. coli* BL21(DE3)pLysSNew England BiolabsCat\# C2527I*E. coli* NEB5-alphaNew England BiolabsCat\# C2987I**Chemicals, Peptides, and Recombinant Proteins**AmpicillinMelford Laboratories, Sigma-AldrichCat\# A0104, Cat\# A9518KanamycinMelford Laboratories, Sigma-AldrichCat\# K0126, Cat\# K4000ChloramphenicolSigma AldrichCat\# C0378ErythromycinSigma-AldrichCat\# E6376LincomycinVWR (Alfa Aesar)Cat \#AAJ61251SpectinomycinSigma-AldrichCat\# S9007PhleomycinResearch Products InternationalCat\# P20200TetracyclineVWR (Alfa Aesar)Cat\# AAB21408LB BrothResearch Products InternationalCat\# L24061, Cat\# L24065LB Broth High SaltMelford LaboratoriesCat\# L1704Agar, Bacteriological GradeVWR (Hardy Diagnostics)Cat\# 89405-068IPTGSigma-Aldrich, Research Products InternationalCat\# I6758, Cat\# AAJ61251ZnCl~2~Sigma-AldrichCat\# 229997^15^N-NH~4~ClSigma-AldrichCat\# 299251^13^C-glucoseSigma-AldrichCat\# 389374^13^C-^15^N-IsogroSigma-AldrichCat\# 606839Deuterium OxideSigma-AldrichCat\# 151882HEPESMelford LaboratoriesCat\# B2001NaClMelford LaboratoriesCat\# S0520MgCl~2~Melford LaboratoriesCat\# M0535KClMelford LaboratoriesCat\# P0515ImidazoleMelford LaboratoriesCat\# B4005cOmplete mini EDTA-free protease inhibitor tabletsRocheCat\# 11836170001TCEPAlfa AesarCat\# J60316.09DTTSigma-AldrichCat\# D0632PMSFSigma-AldrichCat\# P7626GlycerolVWRCat\# 24388.295DNAse I grade IIRocheCat\# 10104159001LysozymeSigma AldrichCat\# L6876**Critical Commercial Assays**Q5 Site-Directed Mutagenesis KitNew England BiolabsCat\# E0554SQuikChange Mutagenesis KitAgilent TechnologiesCat\# 200517Gibson Assembly Master MixNew England BiolabsCat\# E2611SNEBuilder HiFi DNA Assembly Master MixNew England BiolabsCat\# E2621S**Deposited Data**Solution structure of CsfB 1-48This studyPDB: [5N7Y](pdb:5N7Y){#intref0035}Chemical shift assignment of CsfB 1-48This studyBMRB: [34102](ncbi-mmdb:34102){#intref0040}**Experimental Models: Organisms/Strains***B. subtilis*: Parent strain PY79[@bib51]N/A*B. subtilis*: Strain AHB98 (*ΔsigG*::*kan*)[@bib3]N/A*B. subtilis*: Strain AHB199 (*ΔcsfB*::*tet*)[@bib3]N/A*B. subtilis*: Strain AHB201 (*ΔsigE*::*erm*)This studyN/A*B. subtilis*: Strain SFB31 (*ΔsigE*::\[*erm*\]::*phleo*)This studyN/A*B. subtilis*: Strains used for *in vivo* σ^G^ and σ^E^ inhibition assays, see [Table S5](#mmc1){ref-type="supplementary-material"}This studyN/A**Oligonucleotides**Primers used for plasmid construction, see [Table S4](#mmc1){ref-type="supplementary-material"}Integrated DNA TechnologiesN/ASynthetic gene fragments used for plasmid constructionIntegrated DNA TechnologiesN/A**Recombinant DNA**Plasmid: pET-46NovagenCat\# 71335-3Plasmid: pNIC28Structural Genomics ConsortiumCat\# 26103Plasmid: pLATE31Thermo ScientificCat\# K1261Plasmid: pET28_TxrAJosé Manuel Pérez CañadillasN/APlasmid: pDR110David RudnerN/APlasmid: pDR111David RudnerN/APlasmid: pDG1664[@bib19]N/APlasmid: pAH321[@bib38]N/APlasmid: pAH328This studyN/APlasmid: pEr::Pm[@bib44]N/APlasmids constructed for expression of CsfB, σ^G^, or σ^E^ in *E. coli* or *B. subtilis*, see [Table S3](#mmc1){ref-type="supplementary-material"}This studyN/APlasmids harboring σ^G^- or σ^E^-dependent luciferase reporters, see [Table S3](#mmc1){ref-type="supplementary-material"}This studyN/A**Software and Algorithms**Topspin 3Bruker Biospin<https://www.bruker.com/service/support-upgrades/software-downloads/nmr.html>NMRPipe/NMRDraw[@bib11]<http://www.nmrpipe.com/>CcpNMR Analysis 2.2[@bib47]<http://www.ccpn.ac.uk/v2-software/software/analysis>ARIA2.3[@bib37]<http://aria.pasteur.fr/downloads>TALOS+[@bib41]<https://spin.niddk.nih.gov/bax/software/TALOS/>MOLMOL[@bib25]<http://www.msg.ucsf.edu/local/programs/molmol/manual.html>PyMOLDeLano Scientific LLC<http://www.pymol.org>MicroCal Origin 7OriginLab<https://www.originlab.com/>Gen5 Microplate Reader and Imager SoftwareBioTek Instruments<https://www.biotek.com/>ExcelMicrosoft Corporation<https://office.microsoft.com/excel/>PrismGraphPad Software<https://www.graphpad.com/>**Other**HisTrap FF crude column pre-packed with Ni Sepharose resinGE Healthcare Life SciencesCat\# 17-5286-01Superdex75 16/60 PG columnGE Healthcare Life SciencesCat\# 17-1068-01

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rivka Isaacson (<rivka.isaacson@kcl.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

*In vivo* functionality tests of CsfB variants were performed in *B. subtilis* strains isogenic with the laboratory strain PY79 ([@bib51]). For general propagation, *B. subtilis* strains were grown at 37°C in liquid LB media or on LB agar plates.

Method Details {#sec4.4}
--------------

### Plasmid Construction {#sec4.4.1}

Plasmids used in this study are listed in the [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S3](#mmc1){ref-type="supplementary-material"}. The sequences of oligonucleotides used in plasmid construction are given in [Table S4](#mmc1){ref-type="supplementary-material"}. Chromosomal DNA from *B. subtilis* strain PY79 served as a template for polymerase chain reaction (PCR), unless otherwise noted. Sequences of synthetic gene fragments (gBlocks, Integrated DNA Technologies) used in plasmid construction are available upon request. Plasmids were constructed using traditional cloning techniques, site-directed mutagenesis, ligation-independent cloning ([@bib1]), or isothermal assembly ([@bib16]), as indicated. Plasmids were propagated in the *E. coli* strain NEB 5-alpha grown in the presence of the antibiotics ampicillin (100 μg/mL) or kanamycin (50 μg/mL), when appropriate. Site-directed mutagenesis was performed either with the Q5 Site-Directed Mutagenesis Kit or QuikChange Mutagenesis Kit. Isothermal assembly was performed with either the Gibson Assembly Master Mix or the NEBuilder HiFi DNA Assembly Master Mix. All plasmids were verified by DNA sequencing. Construction details for plasmids not previously published are given below.

To generate plasmids for expression and purification of recombinant CsfB from *E. coli*, the *csfB* coding sequence was amplified by PCR using primers listed in [Table S4](#mmc1){ref-type="supplementary-material"} and inserted by ligation independent cloning into pET-46 (N-terminal hexahistidine tag), pNIC28 (TEV protease-cleavable N-terminal hexahistidine tag), and pLATE31 (C-terminal hexahistidine tag), respectively. Plasmids encoding CsfB^A48E^ and other CsfB variants were obtained by site-directed mutagenesis of the pNIC28-CsfB plasmid using the Q5 Site-Directed Mutagenesis Kit.

The plasmid for expression and purification of recombinant σ^G^ from *E. coli* was generated by ligation independent cloning of a PCR product harboring the full-length *sigG* coding sequence into pET-46 (N-terminal hexahistidine tag). The plasmid for expression and purification of σ^E^ (lacking its N-terminal membrane-anchored pro-sequence) from *E. coli* was constructed by ligating a BamHI/XhoI-digested PCR product harboring *sigE* codons 17-239 into BamHI/XhoI-digested pET28-TxrA (gift of Dr J.M. Pérez-Cañadillas, Rocasolano Physical Chemistry Institute, Spain), an *E. coli* expression plasmid containing a TEV protease cleavable N-terminal hexahistidine and thioredoxin tags.

To construct the plasmid (pJJ46) for induction of σ^G^ expression in *B. subtilis*, the *sigG* 5' leader (including the native *sigG* ribosome binding site \[RBS\]) and coding sequence was amplified by PCR with primers JJ30 and JJ31 and assembled into SalI/NheI-digested pDR110 (gift of David Rudner, Harvard Medical School). The plasmid (pSFO1) for induction of σ^E^ (lacking its N-terminal membrane-anchored pro-sequence) in *B. subtilis* was constructed by assembling a synthetic gene fragment harboring *sigE* codons 17-239 preceded by an optimized RBS into SalI/SphI-digested pDR111 (gift of David Rudner, Harvard Medical School). The plasmid (pAH88) for IPTG-induction of CsfB in *B. subtilis* was generated in two steps. First, the *csfB* 5' leader (including the native RBS) and coding sequence were amplified using primers AH41 and AH42, digested with HindIII and NheI, and cloned into HindIII/NheI-digested pDR111 (gift of David Rudner, Harvard Medical School), yielding the intermediate plasmid pAH84. The EcoRI/BamHI fragment containing P~*spank*~*-csfB* and *lacI* was then subcloned into the respective sites of pDG1664 ([@bib19]) to generate pAH88. The derivatives of pAH88 encoding CsfB variants A48E, V37A, V37E, I38A, I38E, V37A/I38A, or the CsfB^1-48^ truncation (pKF70, pKF87-pKF91, and pTK2, respectively) were constructed by individually assembling synthetic gene fragments into the HindIII/SphI-digested pAH88 backbone.

Plasmids encoding luciferase reporter genes were constructed using the plasmid pAH328, which harbors the *Photorhabdus luminescens* bacterial luciferase operon *luxABCDE* optimized for expression in *B. subtilis* and preceded by a multiple cloning site (MCS). This plasmid was constructed from pAH321 ([@bib38]) in two steps. First, the BamHI site upstream of the *luxE* coding sequence in pAH321 was mutated by site-directed mutagenesis using the QuikChange Mutagenesis Kit and primers AH312 and AH313, yielding pAH325. Second, a DNA fragment harboring an EcoRI-SacI-NotI-SpeI-SalI MCS, generated by annealing oligonucleotides AH310 and AH311, was ligated into the EcoRI/SalI-digested backbone of pAH325, yielding pAH328. The σ^E^- and σ^G^-dependent luciferase reporter plasmids (pAH334 and pAH336, respectively) were constructed by ligating EcoRI/SalI-digested PCR products containing either the σ^E^-dependent *spoIID* promoter (amplified with AH58 and AH59) or the σ^G^-dependent *sspB* promoter (amplified with AH60 and AH61) into EcoRI/SalI-digested pAH328.

### *B. subtilis* Strain Construction {#sec4.4.2}

The full genotypes of *B. subtilis* strains used in this study, all of which were derived from the wild type laboratory strain PY79 ([@bib51]), are listed in the [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S5](#mmc1){ref-type="supplementary-material"}. Strains were constructed by transformation of competent cells, prepared as previously described ([@bib50]), with *B. subtilis* chromosomal DNA, plasmid DNA, or PCR-amplified DNA. Transformants were selected on media with antibiotics, when appropriate, as follows: chloramphenicol (5 μg/mL), erythromycin plus lincomycin (1 μg/mL and 25 μg/mL, respectively), spectinomycin (100 μg/mL), kanamycin (5 μg/mL), phleomycin (0.4 μg/mL), and tetracycline (10 μg/mL). Insertions into *amyE* or *thrC* were confirmed by loss of α-amylase activity on LB agar plates with starch or the failure to grow on minimal media, respectively.

The Δ*csfB*::*tet* (AHB199) and *ΔsigG*::*kan* (AHB98) deletions have been described ([@bib3]). The *ΔsigE*::\[*erm*\]::*phleo* deletion was built for this study in two steps. First, a *ΔsigE*::*erm* deletion strain (AHB201) was constructed by the long-flanking homology PCR (LFH-PCR) method ([@bib48]). Primers sets AH43/AH44 and AH45/AH46 were used to amplify sequences flanking *sigE*, which were then used to amplify the erythromycin resistance cassette (*erm*) from plasmid pAH52 ([@bib15]). Proper integration of the resulting *ΔsigE*::*erm* LFH-PCR product was confirmed by PCR. To switch the antibiotic resistance of the *ΔsigE* deletion, AHB201 was transformed with pEr::Pm ([@bib44]), resulting in the erythromycin-sensitive, phleomycin-resistant strain SFB31 (*ΔsigE*::\[*erm*\]::*phleo*).

All other constructs (IPTG-inducible *sigG*, *sigE*, and *csfB*, as well as the σ^E^- and σ^G^-dependent luciferase reporters) were introduced into *B. subtilis* strains using plasmids constructed for this study.

### Recombinant Protein Production {#sec4.4.3}

The plasmids encoding CsfB, σ^G^ or σ^E^ (see the [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S3](#mmc1){ref-type="supplementary-material"}) were transformed into the BL21(DE3)pLysS *E. coli* strain. Cells were grown either in LB or minimal media supplemented with 0.7 g/l ^15^N-NH~4~Cl, 2 g/l ^13^C-glucose and 1 g/l ^13^C-^15^N-Isogro. Protein expression was induced with 0.5 mM IPTG at OD~600~ = 0.8 and conducted either at 37°C for 4 hours or at 18°C overnight. ZnCl~2~ at a final concentration of 10 μM was added to minimal media cell culture before IPTG induction for production of CsfB.

The cell pellet was resuspended in 50 mM HEPES pH 7.5, 300 mM NaCl, 5 mM Imidazole, 5% Glycerol, 1 mM DTT, 1 mg/ml lysozyme, 10 μg/ml Dnase I, 5 mM MgCl~2~, 3x EDTA-free Complete Protease Inhibitor and 2 mM phenylmethylsulfonyl fluoride (PMSF), then lysed by sonication. Recombinant protein was purified from the soluble fraction of the cell lysate by affinity chromatography using a ready-to-use HisTrap FF crude column pre-packed with Ni Sepharose resin. When required, the N-terminal His-tag was removed by overnight incubation at 4°C with TEV protease at a molar ratio protein:TEV of 40:1. The digested protein was then separated from undigested protein and TEV protease using HisTrap FF crude column pre-packed with Ni Sepharose resin. Purified fractions were subjected to a final step of size exclusion chromatography using a Superdex75 16/600 PG column equilibrated with 50 mM HEPES pH 7.5, 150 mM KCl and 0.5 mM TCEP buffer.

The purity and stability of the proteins were checked by SDS-PAGE and mass spectrometry and the presence and stoichiometry of zinc in CsfB was determined by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) using a PerkinElmer NexION 350D spectrometer.

### NMR Spectroscopy {#sec4.4.4}

Uniformly ^15^N, ^13^C-labelled NMR sample was buffer-exchanged into 50 mM HEPES pH 7.5, 150 mM KCl, 0.5 mM TCEP using a HiLoad 16/600 Superdex 75 pg gel filtration column. NMR experiments were carried out on samples \>500 μM at 303 K and recorded on Bruker AVANCE spectrometers operating at 500 MHz, 700 MHz and 950 MHz with TXI cryoprobes controlled by Topspin 3 (Bruker Biospin Ltd). Spectra were processed using NMRPipe/NMRDraw ([@bib11]) and analyzed using CcpNMR Analysis 2.2 ([@bib47]). Backbone resonances were assigned in a standard manner using \[^1^H,^15^N\]-HSQC, HNCA, HNCACB, CBCA(CO)NH, and HNCO experiments ([@bib18]). Side-chains resonances assignment was performed using a combination of HCCH-TOCSY ([@bib24]) and HBHA(CO)NH ([@bib18]). NOE distance restraints and assignments of aromatics rings were obtained from ^15^N-edited NOESY-HSQC and ^13^C-edited NOESY-HSQC spectra with a 120 ms mixing time. An additional set of intermolecular distance restraints was obtained from a ^12^C-filtered, ^13^C-edited NOESY-HSQC spectrum ([@bib52]) using a mixed CsfB dimer prepared by mixing ^15^N, ^13^C-labelled CsfB and unlabelled CsfB in an equimolar ratio. To allow the exchange of the monomeric subunits, the mixture was heated at 50°C for 10 minutes and then cooled slowly.

### Structure Calculation {#sec4.4.5}

The solution structure of the CsfB^1-48^ dimer was solved using ARIA2.3 ([@bib37]), utilizing distance restraints derived from the four NOESY spectra (NOEs from the filtered NOESY experiment were defined as intermolecular while the NOEs in the other NOESY experiments were treated as ambiguous) and dihedral angle restraints estimated by TALOS+ ([@bib41]). Typical annealing parameters were used for distance (10, 15, 50 and 100 Kcal/mol for high temperature, initial cool1, final cool1 and cool2 force constants) and dihedral restraints (50, 150 and 200 Kcal/mol for high temperature, cool1 and cool2 force constants) and a C2 symmetry was imposed with a non-crystallographic symmetry restraints force constant value of 100 Kcal/mol and packing force constants of 15, 10 and 5 Kcal/mol during high temperature, cool1 and cool2 steps.

In the first rounds of calculation, zinc coordination information was not included and, only after checking that the putative involved cysteine residues appeared at the correct disposition for tetrahedral coordination, were the appropriate restrictions for the zinc fingers added (using ARIA2.3 tools). Twenty structures with the lowest energy values were selected out of 200 and subjected to a water refinement process. The final ensemble of the structure (PDB: [5N7Y](pdb:5N7Y){#intref0105}) was analyzed and represented using MOLMOL ([@bib25]) and PyMOL.

### NMR Titrations {#sec4.4.6}

Chemical shift perturbation assays were carried out at 298K using a Bruker AVANCE spectrometer operating at 950 MHz with a TXI cryoprobe controlled by Topspin 3 (Bruker Biospin Ltd). Spectra were processed using NMRPipe/NMRDraw ([@bib11]) and analyzed using CcpNMR Analysis 2.2 ([@bib47]). 100 μM ^15^N-labelled CsfB^A48E^ in 50 mM HEPES pH 7.5, 150 mM KCl, 0.5 mM TCEP was titrated with unlabelled σ^G^ or σ^E^ up to a ratio of 1:2 molar equivalents. ^1^H--^15^N SOFAST-HMQC spectra were recorded at each titration point.

### ITC {#sec4.4.7}

Binding of CsfB^A48E^ to σ^G^ or σ^E^ was measured by ITC using an ITC200 instrument (Microcal Inc. Malvern). Samples were dialyzed into 50 mM HEPES pH 7.5, 150 mM KCl, 0.5 mM TCEP. Titrations were carried out at 25°C using 19 injections of 2 μl with a delay of 180s between injections. For the CsfB^A48E^ interaction with σ^G^ the sample cell contained 110 μM σ^G^ and the syringe 1.6 mM CsfB^A48E^. For the CsfB^A48E^ interaction with σ^E^ the sample cell contained 60 μM CsfB^A48E^ and the syringe 395 μM σ^E^.

### *In Vivo* σ^G^ and σ^E^ Inhibition Assay {#sec4.4.8}

To measure CsfB-mediated σ^G^ and σ^E^ inhibition *in vivo*, *B. subtilis* strains harboring σ^G^- or σ^E^-dependent luciferase reporter genes were engineered to induce expression of the corresponding sigma factors either alone or in combination with wild type or mutant CsfB. Equal amounts of vegetatively growing cells (1 OD~600~⋅mL) were collected and concentrated 5-fold. 30 μl of these cells were applied onto 200 μl LB agar pads containing 100 μM IPTG (for σ^G^ activity assays) or 10 μM IPTG (for σ^E^ activity assays) in white 96-well plates. Bioluminescence from each well was measured at 37°C every 15 min for 6 hours using a Synergy H1M plate reader (BioTek Instruments). Data is reported as the average of at least two (typically three or more) different experiments, with 2-4 technical replicates performed per experiment. CsfB inhibition was calculated as the percentage reduction in σ^G^ or σ^E^ activity (with background reporter activity subtracted) after 4 or 3 hours of induction, respectively, relative to the total σ^G^ or σ^E^ activity (also with background reporter activity subtracted) in a strain lacking inducible *csfB*.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### ITC Analysis {#sec4.5.1}

The obtained data from ITC titrations were analyzed using MicroCal Origin 7 software. Areas under the peaks were integrated and fitted by least-square procedures assuming a 1:1 stoichiometry.

### *In Vivo* σ^G^ and σ^E^ Inhibition Assay {#sec4.5.2}

Data obtained from the *in vivo* σ^G^ and σ^E^ inhibition assays was collected using the Gen5 Microplate Reader and Imager Software (BioTek Instruments) and subsequently analyzed using Excel (Microsoft Corporation) and Prism (Graphpad Software). Variation in the data was determined by calculating the standard deviation across separate experiments.

Data and Software Availability {#sec4.6}
------------------------------

The coordinates of the final ensemble of CsfB structure are deposited at the Protein Data Bank Europe (<https://www.ebi.ac.uk/pdbe/>) under the accession code [5N7Y](pdb:5N7Y){#intref0115}. The assigned chemical shifts of the protein are also deposited at the Biological Magnetic Resonance Bank (<http://www.bmrb.wisc.edu/>) under the accession number [34102](ncbi-mmdb:34102){#intref0125}.
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